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CD4+ T cell expression of the IL-10
receptor is necessary for facial motoneuron
survival after axotomy
Elizabeth M. Runge1,2*, Abhirami K. Iyer3, Deborah O. Setter1,2, Felicia M. Kennedy1,2, Virginia M. Sanders4 and
Kathryn J. Jones1,2

Abstract
Background: After peripheral nerve transection, facial motoneuron (FMN) survival depends on an intact CD4+ T
cell population and a central source of interleukin-10 (IL-10). However, it has not been determined previously
whether CD4+ T cells participate in the central neuroprotective IL-10 cascade after facial nerve axotomy (FNA).
Methods: Immunohistochemical labeling of CD4+ T cells, pontine vasculature, and central microglia was used to
determine whether CD4+ T cells cross the blood-brain barrier and enter the facial motor nucleus (FMNuc) after FNA. The
importance of IL-10 signaling in CD4+ T cells was assessed by performing adoptive transfer of IL-10 receptor beta (IL10RB)-deficient CD4+ T cells into immunodeficient mice prior to injury. Histology and qPCR were utilized to determine
the impact of IL-10RB-deficient T cells on FMN survival and central gene expression after FNA. Flow cytometry was used
to determine whether IL-10 signaling in T cells was necessary for their differentiation into neuroprotective subsets.
Results: CD4+ T cells were capable of crossing the blood-brain barrier and associating with reactive microglial nodules
in the axotomized FMNuc. Full induction of central IL-10R gene expression after FNA was dependent on CD4+ T cells,
regardless of their own IL-10R signaling capability. Surprisingly, CD4+ T cells lacking IL-10RB were incapable of mediating
neuroprotection after axotomy and promoted increased central expression of genes associated with microglial
activation, antigen presentation, T cell co-stimulation, and complement deposition. There was reduced differentiation of
IL-10RB-deficient CD4+ T cells into regulatory CD4+ T cells in vitro.
Conclusions: These findings support the interdependence of IL-10- and CD4+ T cell-mediated mechanisms of
neuroprotection after axotomy. CD4+ T cells may potentiate central responsiveness to IL-10, while IL-10 signaling within
CD4+ T cells is necessary for their ability to rescue axotomized motoneuron survival. We propose that loss of IL-10
signaling in CD4+ T cells promotes non-neuroprotective autoimmunity after FNA.
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Background
Maintenance of central motoneuron survival is paramount
in order for functional recovery to be achieved following
peripheral nerve transection and disconnection from target
musculature. After facial nerve axotomy (FNA), immunodeficient mice lacking B and T cells exhibit more facial
motoneuron (FMN) death in the facial motor nucleus
(FMNuc) compared to wild-type (WT) mice with intact
immune systems [1, 2]. In the FNA model of peripheral
nerve injury, the neuroprotective capacity of the adaptive
immune system is specific to Th2 CD4+ T cells, which are
sufficient for rescuing FMN survival when adoptively transferred into immunodeficient RAG-2-/- mice [3, 4]. The precise mechanism of CD4+ T cell-mediated neuroprotection
is unknown, but recent research shows that the peripheral
immune system plays a major role in modulating the central glial response to facial nerve injury [5].
Naïve CD4+ T cells must encounter major histocompatibility complex (MHC) class II on antigen presenting
cells (APCs) in the periphery and become activated in an
antigen-specific fashion in order to become neuroprotective [6]. After peripheral activation and clonal expansion, T
cells are next attracted to the FMNuc by centrally derived
chemokines [7–9]. It has been inferred from immunohistochemical (IHC) studies demonstrating the presence of
CD3+ T lymphocytes in axotomized FMNuc that these
cells cross the blood-brain barrier (BBB) [10–12]. However, further evidence utilizing histological labeling of the
FMNuc vasculature is needed to strengthen the hypothesis
that T cells (and the CD4+ T subset in particular) exist in
CNS parenchyma after axotomy and are not confined to
penetrating blood vessels, which are difficult to visualize
without appropriate labeling techniques. After homing to
the injured FMNuc, T cells must again encounter MHC
class II on microglia in order to confer neuroprotection
[6]. Microglia proliferate in the FMNuc after axotomy [13],
phagocytize dead neurons [14], and express MHC class I
and II molecules, on which they may present neuronal
antigen to infiltrating T cells [15, 16].
The anti-inflammatory cytokine interleukin-10 (IL-10)
has received considerable attention in neuroinflammation
research due to its modulatory effects on glial reactivity
and pro-survival influences on neurons [17, 18]. IL-10 is an
important mediator of the neuroprotective capability of
CD4+ T cells after FNA; in the absence of IL-10, axotomy
induces greater FMN death that is resistant to rescue by
CD4+ T cells. Yet, despite the necessity of both IL-10 and
CD4+ T cells for neuroprotection after FNA, CD4+ T cells
are not a requisite source of IL-10. IL-10 likely derives from
CNS resident cells in the FMNuc, rather than CD4+ T
cells. Although absence of CD4+ T cells results in slightly
decreased IL-10 levels in the FMNuc at an early time point
after axotomy, this modest difference is unlikely to wholly
explain the survival deficit observed in RAG-2-/- mice at
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1 month post-operation [19]. It has not been elucidated
previously whether the dual actions of IL-10- and CD4+ T
cell-mediated neuroprotection after FNA are interrelated
or independent of one another. This information is necessary to understand the process of endogenous immunemediated neuroprotection and thereby identify potential
mechanisms that can be exploited for the treatment of
nerve injury and motoneuron disease.
For the first part of this study, it was hypothesized that
CD4+ T cells play an integral role in the central IL-10
cascade after FNA by regulating IL-10 receptor (IL-10R)
expression in the FMNuc. The ability of peripheral CD4+
T cells to regulate central gene expression in the axotomized FMNuc has been previously established [5]. Prior to
testing this hypothesis, it was necessary to determine
whether T cells must communicate with cells in the
FMNuc remotely (i.e., across the BBB) or are capable of
traveling into the FMNuc parenchyma and interacting directly with resident cells there. This information would indicate whether central expression of IL-10R and other
markers are potentially effected by direct T cell contact.
The second part of this study was performed to investigate IL-10R expression by infiltrating T cells themselves.
IL-10 directly induces T cell tolerance to specific antigen
[20]. Furthermore, it has been shown that tolerized T cells
can inhibit further antigen presentation events and suppress the proliferation of other T cells in an antigenspecific fashion [21, 22]. Conversely, effector T cells (particularly Th1 and Th17 cells) can activate APCs (including
microglia) to a pro-inflammatory state [23–26]. Therefore,
an IL-10 cascade in the axotomized FMNuc could reflect a
mechanism regulating autoimmune responses to neuronal
self-antigen released after FNA. We propose that IL-10R
expression on CD4+ T cells is necessary for their ability to
confer neuroprotection, potentially by influencing T cell
activation against self-antigen and subsequent modulation
of the glial microenvironment by T cells after axotomy.

Methods
Animals: all mice were obtained from The Jackson Laboratory. Strains utilized include C57BL/6 J (WT), B6(Cg)Rag2tm1.1Cgn/J (RAG-2-/-), and B6.129S2-Il10rbtm1Agt/J
(Il10rb-/-). Only female mice were used due to the tendency
of males to engage in fighting behavior after axotomy, leading to infections at the surgery site that complicate immune
profiles. Animals were obtained at 7 weeks of age and
allowed to acclimate for at least 1 week prior to use. Mice
were housed in sterilized microisolator cages equipped with
a laminar flow system to maintain a pathogen-free environment and allowed access to autoclaved food pellets and
water ad libitum.
Adoptive transfer: donor animals were utilized at a 1:1
ratio to recipients. Following CO2 euthanasia and cervical
dislocation, spleens were removed and mechanically
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dissociated using the plunger of a sterile syringe. Dissociated splenocytes were incubated with CD4 magnetic beads
(Miltenyi Biotec, 130-117-043) and manually sorted using
LS columns (Miltenyi Biotec, 130-042-401) following
manufacturer instructions. The eluent was then passed
through a new column a second time to enhance cell purity. Flow cytometry revealed sorted CD4+ T cell purity to
be 96% (data available upon request). Host mice received 5
million sorted CD4+ T cells per 100 μl PBS injection via tail
vein 1 week prior to FNA to allow for engraftment of transferred cells.
Surgical procedure: FNA was performed when mice
were 8 weeks old. The detailed surgical procedure has
been published previously [27]. Briefly, animals were
anesthetized with 2.5% isoflurane, and a small (~ 4 mm)
incision was made posterior to the right ear protuberance using aseptic techniques. The underlying fascia was
dissected bluntly to expose the facial nerve, which was
severed just distal to its emergence from the stylomastoid foramen. The nerve stumps were either pushed
away, or a small segment of the distal nerve stump was
resected to prevent reconnection. The left facial nerve
was left intact as an internal control. Following surgery,
successful transection of the facial nerve was confirmed
by behavioral assessment of eye blink and whisking
reflexes.
Immunohistochemistry: The 14 days post-operation
(dpo) time point was selected for analysis as this represents the peak of T cell infiltration in the literature [11,
16]. Animals (n = 3) were euthanized via ketaminexylazine overdose and exsanguination followed by perfusion with 2% buffered paraformaldehyde (PFA). Brains
were removed, post-fixed in 2% PFA for 1–3 h, and
equilibrated in 30% sucrose prior to embedding in OCT
medium. Eight micrometer brainstem sections containing the FMNuc were collected and blocked for 1 h at
room temperature in 10% donkey serum, 1% bovine
serum albumin, and 0.01% Triton X-100 in PBS,
followed by incubation in primary antibody (Table 1) for
Table 1 Antibodies utilized for IHC

Primary

Antibody

Manufacturer
and Cat. no.

Dilution

Rabbit anti-IBA1

Thermo Fisher
019-19741

1:500

Rat anti-CD4 488

BioLegend
100423

1:100

Rabbit anti-CD3

Abcam ab16669

1:200

Rabbit anti-CD31

Abcam
ab124432

1:500

Secondary Donkey anti-rabbit 568
Abcam ab175470
(used for IBA1, CD3, CD31)
Donkey anti-rat 488 (used
for CD4)

Thermo Fisher
A21208

1:1000
1:1000

4 h at room temperature or 16 h at 4 °C. Sections were
washed 3 × 5 min in PBS prior to incubation with secondary antibody for 1 h at room temperature. When
fluorescent Nissl staining was desired, NeuroTrace™ 435/
455 Blue Fluorescent Nissl Stain (Thermo Fisher,
N21479) was diluted 1:100 in PBS, applied to sections
for 20 min after removing secondary antibody, and
washed 3 × 5 min in PBS prior to mounting in ProLong™
Gold Antifade medium (Invitrogen, P36930). Images
were captured with an Olympus BX50 inverted fluorescent microscope using the Olympus cellSens Entry 1.9
software, and level adjustments to reduce background
were performed uniformly across control and axotomized FMNuc in Adobe Photoshop.
Motoneuron counting: animals (n = 4–5/group) were
euthanized at 28 dpo using CO2 inhalation and cervical
dislocation. Brains were removed and flash-frozen at the
interface of a pre-chilled 37.5% 2-methylbutane/62.5% 1bromobutane biphasic solution prior to cryosectioning.
Brainstem sections spanning the caudal-rostral extent of
the FMNuc were collected at 25 μm, fixed for 15 min in
4% PFA, and stained with 0.04% thionin acetate solution
followed by ethanol dehydration series. Sections were
cleared in CitriSolv overnight or up to 3 days and subsequently coverslipped using Permount toluene-based
mounting medium. For counting, an impartial investigator coded all slides. A separate blinded investigator used
a Leica DMRB light microscope and Neurolucida software (version 10.31) to manually count motoneurons in
the FMNuc. To avoid double counting, only FMN profiles with a nucleus and nucleolus were counted. Mean
percentage FMN survival was quantified by dividing the
total number of FMN on the axotomized side by the
total number on the control side and multiplying by
100%. One-way analysis of variance (ANOVA) followed
by a Student-Newman-Keuls post-hoc test was performed with an alpha of 0.05.
Laser capture microdissection, RNA extraction, reverse
transcription (RT), and qPCR: N = 4-11 mice/group
were analyzed at the 14 dpo time point according to the
rationale described in previous experiments; additionally,
this time point represents the peak of microglial gene
expression in the FMNuc after axotomy [5]. All procedures were performed as described in Setter et al. [5].
Briefly, brains were removed, flash-frozen, and sectioned
onto PEN membrane slides (Leica Microsystems,
11505158). Slides were stained with thionin, and a Leica
ASLMD microscope was used to collect the right and
left FMNuc. RNA extraction and RT were performed
using an Arcturus PicoPure® RNA Isolation Kit (Applied
Biosystems, KIT0204) and SuperScript® VILO Master
Mix (Invitrogen, 11755050), respectively. TaqMan® FAM
gene expression assays were used to perform qPCR
(Table 2). CT values were normalized to the reference
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Table 2 TaqMan® assays utilized in this study
Gene

TaqMan ID

RefSeq accession number

B2m

Mm00437762_m1

NM_009735.3

C3

Mm01232779_m1

(GenBank–no RefSeq numbers
available) BC029976.1, BC043338.1,
DQ408205.1, EU868829.1,
HM856604.1, K02782.1

Cd40

Mm00441891_m1

NM_011611.2, NM_170702.2,
NM_170703.2, NM_170704.2,
NR_027852.1

Cd86

Mm00444543_m1

NM_019388.3

Gapdh

Mm99999915_g1

NM_001289726.1, NM_008084.3

H2ab1

Mm00439216_m1

NM_207105.3

Nos2

Mm00440502_m1

NM_010927.3

Tnf

Mm00443260_g1

NM_013693.3

gene Gapdh and fold changes in mRNA expression between axotomized and control FMNuc were calculated.
Because Tnf is only expressed on the axotomized FMNuc,
the ΔΔCT value was calculated using a spleen cDNA
standard, and its levels in axotomized FMNuc are
expressed relative to WT spleen. The same spleen standard
was used for comparison across all samples. Outliers were
detected using the Grubbs’ test (GraphPad QuickCalcs).
One-way ANOVA followed by Student-Newman-Keuls
multiple comparisons was performed with an alpha of 0.05
to determine significance.
Cell culture: anti-CD3e (BD Biosciences, 553057) at
10 μg/mL concentration in sterile PBS was incubated on 6well flat-bottom tissue culture plates overnight at 4 °C.
Spleens (n = 3/group) were dissociated in sterile FACS buffer, subjected to RBC lysis, and resuspended in RPMI 1640
supplemented with 10% heat inactivated FBS, 2 mM L-glutamine, 50 μM β-mercaptoethanol, and 1% penicillin/
streptomycin. 4–6 × 106 cells were deposited per well on
pre-incubated and washed plates (stimulated cells) or PBS-
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only plates (unstimulated cells). Two micrograms per milliliter of anti-CD28 (BD Biosciences, 553294) was added to
the stimulated cells, and plates were incubated overnight at
37 °C. The next day, cells were stimulated further with 10
ng/ml PMA and 1000 ng/ml ionomycin for 4–6 h. Brefeldin A was added at 10 μg/ml for the last 3 h to all wells
(both stimulated and unstimulated).
Flow cytometry: cells were harvested and blocked with
anti-CD16/CD32 at 1:1000 in FACS buffer for 15 min before washing and staining for surface markers TCRβ and
CD4 for 30 min on ice. Cells were washed, fixed in 1% PFA
for 15 min, and washed again prior to permeabilization in
FACS buffer + 0.1% saponin for 15 min at room
temperature. Antibody cocktails for intracellular staining
were mixed in FACS buffer +0.1% saponin and applied to
cells for 30 min at room temperature. Antibody information
can be found in Table 3. Cells were washed, resuspended in
FACS buffer, and stored at 4 °C until flow cytometry was
performed (within 1 day). Data was acquired using a Fortessa X20 flow cytometer. A minimum number of 10,000
events were collected using the BD FACSDiva software.
FCS files were analyzed using FlowJo 10. Cells were first
gated for singlets, and CD4+ T cells and downstream T cell
helper subset populations were defined following the representative gating strategies depicted in Fig. 1. Comparison of
cell populations was performed in GraphPad Prism using
one-way ANOVA followed by Student-Newman-Keuls
multiple comparisons with an alpha of 0.05 to determine
significance.

Results
It is unknown whether the CD4+ T cells responsible for
mediating neuroprotection after axotomy are capable of
infiltrating into the CNS parenchyma, or alternatively
whether they must communicate with CNS resident cells
across the BBB. Previous work using single-label IHC
has reported the presence of CD3+, CD4+, and CD8+

Table 3 Antibodies utilized for flow cytometry
Antibody

Manufacturer and cat. no.

Dilution

APC anti-mouse TCR β chain

BioLegend 109212

1:50

Alexa Fluor 488 anti-mouse CD4

BioLegend 100423

1:800

BV 421 anti-mouse CD4

BioLegend 100437

1:50

BV 711 anti-mouse IL-4

BioLegend 504133

1:50

BV 421 anti-mouse IFN-γ

BioLegend 505829

1:50

BV 711 anti-mouse IL-17A

BioLegend 506941

1:50

BV 711 anti-mouse CD25

BioLegend 102049

1:50

PE anti-GATA3

BioLegend 653803

1:50

PE/Dazzle™ 594 anti-T-bet

BioLegend 644827

1:50

PE anti-RORγt

Invitrogen AFKJS-9

1:50

Alexa Fluor 488 anti-mouse/rat/human FOXP3

BioLegend 320011

1:100

Purified anti-mouse CD16/32

BioLegend 101310

1:1000

Runge et al. Journal of Neuroinflammation

(2020) 17:121

Page 5 of 16

Fig. 1 Diagram depicting representative gating strategies for delineating CD4+ T cell subset populations. Following gating for singlets and debris
exclusion, the CD4+ T cell population was selected based on CD4 and TCRβ expression. Within this population, the Th1 subset was defined as
TBET+IFNγ+, Th2 as GATA3+IL-4+, Th17 as RORγt+IL-17A+, and regulatory T (Treg) helper subset as CD25highFOXP3+

cells in the FMNuc after axotomy [11, 16, 28–30]. However, given the limitations of single-marker IHC as well as
the potential expression of CD4 on non-T cells, including
microglia and macrophages [31], it was necessary to perform co-IHC of CD3 with CD4 to demonstrate that true
CD4+ T cells infiltrate the FMNuc after FNA where they
may potentially interact with centrally located cells.

Antibodies specific for CD3 and CD4 antigen revealed no
infiltrate in the unoperated FMNuc (Fig. 2a). In the contralateral axotomized FMNuc, infiltrates of CD3+ and CD4+
cells were detected (Fig. 2b–f). In every tissue section analyzed, all CD4+ cells observed infiltrating the FMNuc were
CD3+, but not every CD3+ T cell was CD4+, indicating
that CD8+ T cells may also infiltrate the FMNuc after
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Fig. 2 IHC identification of CD3 + CD4+ T cells in the FMNuc. a Control FMNuc at 14 dpo. White dashed line indicates boundary of FMNuc. b Low
power image of axotomized FMNuc at 14 dpo with T cell infiltration. c Higher power image of boxed area in b. d High power image of boxed area in c,
CD4 channel only (green). e Same field as d showing CD3 channel only (red). f Overlaid channels in d and e showing CD3+/CD4− (white arrowhead)
and CD3+/CD4+ T cells. Scale bar in b = 100 μm and applies to a and b. Scale bar in c = 100 μm. Scale bar in d = 50 μm and applies to d–f

axotomy (Fig. 2d–f). Although CD4+ T cells were detected
in the FMNuc after axotomy, this observation alone was
not sufficient to determine whether they are capable of
interacting directly with cells in CNS parenchyma, or
whether they are restricted to the vascular compartment.
In combination with anti-CD4 to label T cells and a fluorescent Nissl stain to label neurons, an antibody against
CD31 was used to visualize vasculature in the FMNuc. This
triple stain revealed the presence of small penetrating blood
vessels in the control FMNuc without evidence of T cell infiltration (Fig. 3a). CD4+ T cells were detectable in the axotomized FMNuc at 14 dpo. These T cells appeared not to
be contained within CD31-labeled blood vessels,

indicating that they are capable of extravasating into
the CNS parenchyma (Fig. 3b–d). Furthermore, some
T cells appeared to be in close proximity to injured
motoneurons (Fig. 3c, d, arrowheads).
CD4+ T cells must interact with MHC class II on a central APC to mediate neuroprotection after axotomy [6].
With the ability of CD4+ T cells to extravasate into the
FMNuc parenchyma established, potential associations of
CD4+ T cells with microglia were next evaluated. Double
labeling for CD4 and IBA1 in the unaxotomized FMNuc
was negative for reactive microglia or infiltrating CD4+ cells
(Fig. 4a). At 14 dpo, microglia in the axotomized FMNuc
became reactive as evidenced by increased expression of
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Fig. 3 IHC of CD4+ T cells (green) and CD31-labeled endothelial layer of blood vessels (red) penetrating the FMNuc. a Composite image of
control FMNuc at 14 dpo showing no infiltrating T cells. b Composite image of axotomized FMNuc at 14 dpo. c, d Magnified fields from boxes in
b showing CD4+ T cells are not contained within CD31-labeled blood vessels. Note, CD4+ T cells marked with arrowheads in close proximity to
FMN labeled with fluorescent Nissl stain (blue). Scale bar in b = 100 μm and applies to a and b. Scale bar in d = 50 μm and applies to c and d

IBA1, and a CD4+ T cell infiltrate was observed (Fig. 4b).
These CD4+ T cells often appeared to be clustered around
reactive microglial nodules (Fig. 4c–h, arrowheads).
To determine whether the adaptive immune system has
an effect on central upregulation of the IL-10R after axotomy, qPCR was performed for IL-10R subunit gene expression in the FMNuc of WT, immunodeficient, and
immune-cell reconstituted mice. Gene expression was calculated as fold change of mRNA expression in axotomized
FMNuc relative to control FMNuc. Fold change in Il10ra
expression (Fig. 5a) was significantly reduced in RAG-2-/(3.97 ± 0.26) compared to WT (5.70 ± 0.35, p < 0.05) and
was restored to WT levels after adoptive transfer of WT
CD4+ T cells (6.12 ± 0.38). Fold change in Il10rb expression (Fig. 5b) was likewise significantly reduced in RAG2-/- (2.06 ± 0.10) compared to WT (2.74 ± 0.15, p < 0.01),
and adoptive transfer of WT CD4+ T cells restored normal Il10rb expression (2.74 ± 0.07). These data indicate
that CD4+ T cells are necessary for full upregulation of
IL-10R subunits in the FMNuc after axotomy.

This regulation of IL-10R expression by CD4+ T cells
could be due to T cell-triggered induction of IL-10R
expression on CNS resident cells and/or infiltration of IL10R-expressing T cells into the FMNuc after axotomy. To
elucidate which scenario occurs after FNA, RAG-2-/- mice
were reconstituted with CD4+ T cells lacking Il10rb expression, which is necessary for IL-10 signal transduction
[32, 33]. Il10ra fold change in RAG-2-/- mice reconstituted
with Il10rb-/- CD4+ T cells (Fig. 5a, 7.54 ± 0.65) was significantly increased relative to RAG-2-/- (p < 0.001), indicating
that IL-10 signaling within T cells was not necessary for T
cells to regulate Il10ra gene expression in the FMNuc. In
fact, upregulation of Il10ra in RAG-2-/- mice given Il10rb-/CD4+ T cells was significantly greater than in WT or
RAG-2-/- given WT CD4+ T cells (p < 0.05), perhaps due
to a compensatory reaction in the FMNuc. Il10rb fold
change in RAG-2-/- reconstituted with Il10rb-/- CD4+ T
cells (Fig. 5b, 2.64 ± 0.09) was significantly increased relative to RAG-2-/- (p < 0.001) and was not significantly different from WT or RAG-2-/- + WT CD4+ T cells. Due to
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Fig. 4 IHC of CD4+ T cells (green) and IBA+ microglia (red) in the FMNuc. Nissl-labeled neurons are shown in blue. a Composite image of control
FMNuc at 14 dpo showing no infiltrating T cells or reactive IBA+ microglia. b Composite image of axotomized FMNuc at 14 dpo. c, d Magnified
fields from boxes in b showing IBA1+ microglial nodules (arrowheads) with associated CD4+ T cells. e–h Representative fields from axotomized
FMNuc in other experimental animals showing IBA1+ microglial nodules (arrowheads) with associated CD4+ T cells. Scale bar in b = 100 μm and
applies to a and b. Scale bar in h = 50 μm and applies to c–h

absence of Il10rb expression by the transgenic T cells, this
restoration of Il10rb gene expression could only be due to
a T cell-mediated induction of Il10rb in CNS resident cells
in the FMNuc.
Although it was found that Il10rb-/- CD4+ T cells were
capable of triggering an increase in IL-10R expression by
CNS resident cells in the FMNuc, the neuroprotective
capacity of these T cells remained unknown. It is well
established in the literature that RAG-2-/- mice exhibit
decreased FMN survival after axotomy relative to WT, and

that WT CD4+ T cells restore FMN survival in RAG-2-/mice to WT levels [2, 3]. The ability of Il10rb-/- CD4+ T
cells to mediate neuroprotection was assayed by quantifying
FMN survival in WT, RAG-2-/-, and RAG-2-/- reconstituted
with Il10rb-/- CD4+ T cells at 28 dpo. In accordance with
the literature, survival in RAG-2-/- was significantly decreased compared to WT (Fig. 6a, 69 ± 1.3% compared to
81 ± 3%, p < 0.05). However, Il10rb-/- CD4+ T cells failed
to rescue FMN survival; survival in reconstituted animals
remained low compared to WT (61.8 ± 3.5%, p < 0.01). To
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Fig. 5 mRNA fold change of a Il10ra and b Il10rb in the axotomized FMNuc relative to control FMNuc at 14 days post-FNA in WT, RAG-2-/-, RAG2-/- + WT CD4+ T cells, and RAG-2-/- + Il10rb-/- CD4+ T cells. Bars represent mean fold change ± SEM. Dotted line represents baseline level of
gene expression in control FMNuc. *p < 0.05, **p < 0.01, ***p < 0.001

confirm that adoptively transferred Il10rb-/- T cells were
still viable in vivo at 28 dpo, IHC was performed using
spleens from WT, RAG-2-/-, and RAG-2-/- mice reconstituted with Il10rb-/- CD4+ T cells. WT spleens contained
CD3+ T cell follicles that were absent in RAG-2-/- spleen
and restored in RAG-2-/- given Il10rb-/- CD4+ T cells (Fig.
6b, c), indicating that transferred cells successfully
engrafted into host lymphoid tissue. Overall, these
data suggest that the increase in IL-10R expression by

CNS resident cells, although mediated by T cells, is
insufficient for FMN survival after FNA; rather, IL10R signaling by the T cell itself may be necessary
for neuroprotection.
To investigate the role of T cell IL-10R signaling in modulating central APC activation after FNA, qPCR for genes associated with microglial activation, antigen presentation, T
cell co-stimulation, and complement deposition/synaptic
pruning was performed in the FMNuc of WT, RAG-2-/-,

Fig. 6 a Average percent survival of axotomized FMN relative to control ± SEM at 28 dpo in WT, RAG-2-/-, and RAG-2-/- reconstituted with Il10rb-/CD4+ T cells. Survival in both RAG-2-/- and RAG-/- reconstituted with Il10rb-/- CD4+ T cells was decreased relative to WT, indicating that Il10rb-/T cells fail to confer neuroprotection. *p < 0.05, **p < 0.01. b IHC showing CD3+ T cells in WT splenic follicles. c CD3+ cells are absent in RAG-2-/spleens. d Adoptive transfer of Il10rb-/- CD4+ T cells restores CD3+ expression in splenic follicles, indicating that Il10rb-/- CD4+ T cells were
successfully transplanted and remain viable in vivo until 28 dpo. Scale bar = 100 μm and applies to b–d
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and RAG-/- mice reconstituted with either WT or Il10rb-/CD4+ T cells. The hypothesis was that loss of IL-10 receptor signaling on T cells would promote a pro-inflammatory,
autoimmune-reactive microglial/macrophage gene signature
in the FMNuc.
Cd68, Cd40, Tnf, and Nos2 were genes selected for evaluation of general microglial pro-inflammatory activation. At
14 dpo, Cd68 mRNA increased approximately sixfold in
the WT axotomized FMNuc; there was no difference in
Cd68 expression between WT, RAG-2-/-, and RAG-2-/mice reconstituted with WT CD4+ T cells (Fig. 7a, 6.078 ±
0.88, 5.809 ± 0.25, 6.785 ± 0.29, respectively). RAG-2-/mice reconstituted with Il10rb-/- CD4+ T cells had significantly increased Cd68 expression in the axotomized
FMNuc (9.37 ± 0.69) relative to WT (p < 0.01), RAG-2-/-,
and RAG-2-/- + WT CD4+ T cells (p < 0.05), indicating
that Il10rb-/- T cells promote an increase in general microglial reactivity after axotomy. Cd40 mRNA was modestly
increased in the axotomized FMNuc relative to control
across all conditions, and there were no significant differences between WT, RAG-2-/-, and RAG-2-/- + Il10rb-/CD4+ T cells (Fig. 7b, 1.57 ± 0.11, 1.46 ± 0.08, 2.17 ± 0.24,
respectively). There was also no significant difference between RAG-2-/- mice reconstituted with WT CD4+ T cells
(2.40 ± 0.25) and those reconstituted with Il10rb-/- CD4+ T
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cells, although the former showed significantly increased
Cd40 expression relative to WT and RAG-2-/- (p < 0.05).
No Tnf transcript was detected in the control FMNuc, in
agreement with previous studies [5, 34]. Therefore, to compare changes in Tnf mRNA expression, the differences between Tnf and Gapdh cycle threshold values were
normalized to the same standardized spleen control for
each axotomized FMNuc sample. As shown in Fig. 7c, Tnf
mRNA in axotomized FMNuc at 14 dpo ranged between
1–3% of spleen standard, and no differences were observed
between WT, RAG-2-/-, RAG-2-/- + WT CD4+ T cell, and
RAG-2-/- + Il10rb-/- CD4+ T cell groups (0.015 ± 0.003,
0.017 ± 0.004, 0.024 ± 0.005, 0.023 ± 0.004, respectively).
Nos2 mRNA did not appear to be upregulated in the axotomized FMNuc and in fact may have slightly decreased relative to control in WT and RAG-2-/- mice receiving Il10rb-/CD4+ T cells (Fig. 7d, results of one-sample t test against
fold change of 1: WT, 0.76 ± 0.05, p = 0.008; RAG-2-/- +
Il10rb-/- CD4, 0.71 ± 0.09, p = 0.033). There were no significant differences detected between these groups and RAG2-/- mice or RAG-2-/- + WT CD4+ T cells (0.87 ± 0.17 and
0.78 ± 0.11, respectively).
H2ab1 and Cd86 were selected for analysis of microglial
antigen presentation and T cell co-stimulation-associated
gene expression in the axotomized FMNuc. H2ab1 encodes

Fig. 7 mRNA fold change of a CD68, b Cd40, c Tnf, and d Nos2 in the axotomized FMNuc relative to control FMNuc (except for Tnf, which is
relative to spleen control) at 14 days post-FNA in WT, RAG-2-/-, RAG-2-/- + WT CD4+ T cells, and RAG-2-/- + Il10rb-/- CD4+ T cells. Bars represent
mean fold change ± SEM. *p < 0.05, **p < 0.01
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Fig. 8 mRNA fold change of a H2ab1 and b Cd86 in the axotomized FMNuc relative to control FMNuc at 14 days post-FNA in WT, RAG-2-/-, RAG2-/- + WT CD4+ T cells, and RAG-2-/- + Il10rb-/- CD4+ T cells. Bars represent mean fold change ± SEM. *p < 0.05, **p < 0.01

the predominant MHC class II haplotype expressed in
C57BL/6 J mice, and CD86 is a co-stimulatory molecule
expressed by microglia that interacts with CD28 on T cells.
Axotomy robustly induced H2ab1 in WT animals; expression increased approximately fivefold relative to control
FMNuc (Fig. 8a). RAG-2-/- mice that received adoptive
transfer of Il10rb-/- CD4+ T cells exhibited dramatically
higher induction of H2ab1 expression after axotomy compared to WT, RAG-2-/-, and RAG-2-/- + WT CD4+ T cells
(12.5 ± 1.88 vs. 4.9 ± 0.71, 6.1 ± 1.12, 5.8 ± 0.89, respectively; p < 0.01). Expression of Cd86 also increased robustly
in response to axotomy with approximate 9-fold induction
in WT (Fig. 8b). RAG-2-/- mice given Il10rb-/- CD4+ T cells
exhibited significantly increased expression of Cd86 after
axotomy compared to WT, RAG-2-/-, and RAG-2-/- + WT
CD4+ T cells (13.7 ± 1.10 vs. 8.9 ± 0.67, 7.9 ± 1.13, 10.1 ±
1.24, respectively, p < 0.05).
Both MHC class I and C3 are associated with microglial
phagocytic nodule formation and synaptic pruning [16,
35–37]. B2m encodes the MHC class I subunit β2microglobulin. B2m mRNA expression increased fivefold in
the WT axotomized FMNuc and was not significantly

different in RAG-2-/- mice (Fig. 9a, 5.0 ± 0.28, 7.2 ± 0.85,
respectively). Adoptive transfer of WT CD4+ T cells into
RAG-2-/- mice resulted in significantly increased B2m expression relative to WT and RAG-2-/- (RAG-2-/- + WT
CD4 11.0 ± 1.02 vs. WT, p < 0.001; vs. RAG-2-/-, p < 0.01).
RAG-2-/- mice given Il10rb-/- CD4+ T cells had significantly increased expression of B2m after axotomy compared to WT, RAG-2-/-, and RAG-2-/- + WT CD4+ T cells
(RAG-2-/- + Il10rb-/- CD4 14.9 ± 0.81 vs. WT and RAG2-/-, p < 0.0001; vs. RAG-2-/- + WT CD4, p < 0.01). C3
mRNA increased modestly in the FMNuc of WT mice
after axotomy and was not significantly different in
RAG-2-/- mice (Fig. 9b, 2.6 ± 0.39, 0.9 ± 0.35, respectively). Adoptive transfer of WT CD4+ T cells into
RAG-2-/- mice resulted in increased C3 expression (5.3
± 1.24 vs. WT, p < 0.05; vs. RAG-2-/-, p < 0.01). Adoptive transfer of Il10rb-/- CD4+ T cells resulted in even
greater C3 expression than in WT, RAG-2-/-, or RAG2-/- + WT CD4+ T cells (9.4 ± 0.86 vs. WT and RAG2-/-, p < 0.0001; vs. RAG-2-/- + WT CD4, p < 0.01).
Flow cytometry was utilized to determine whether loss
of IL-10RB affects T cell subset differentiation. Both

Fig. 9 mRNA fold change of a B2m and b C3 in the axotomized FMNuc relative to control FMNuc at 14 days post-FNA in WT, RAG-2-/-, RAG-2-/- +
WT CD4+ T cells, and RAG-2-/- + Il10rb-/- CD4+ T cells. Bars represent mean fold change ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
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unstimulated and in vitro stimulated splenocytes from
WT and Il10rb-/- mice were included as groups for statistical analysis; in Fig. 10, only data from stimulated cells
are shown. Baseline (unstimulated) numbers of cells
within T cell subsets did not differ between WT and
Il10rb-/- splenocytes and whether expressed as percent
within the overall CD4+ T cell population or as absolute
cell counts (data available upon request). After stimulation, there were no differences between WT and Il10rb-/in populations of Th1 (Fig. 10a, 9.14 ± 0.92% vs. 7.84 ±
1.22%; 41 ± 6.81 vs. 35 ± 7.54), Th2 (Fig. 10b, 55.8 ±
1.46% vs. 53.77 ± 0.72%; 1003 ± 158.8 vs. 748 ± 73.51), or
Th17 cells (Fig. 10c, 57.17 ± 2.89% vs. 63.43 ± 13.82%;
1072 ± 209.3 vs. 709 ± 85.85). There was a small but significant reduction in Tregs in Il10rb-/- compared to WT
splenocytes when analyzed as percent within CD4+ T cell
population (Fig. 10d, 77.93 ± 1.22% in Il10rb-/- vs. 84.5 ±
1.76% in WT, p < 0.05) as well as absolute cell counts
(550 ± 71.01 in Il10rb-/- vs. 771 ± 110.6 in WT, p < 0.05).

Discussion
This study demonstrates that CD3+ CD4+ T cells are indeed capable of crossing the blood-brain barrier into the
FMNuc parenchyma after axotomy, where they may
interact directly with CNS resident cells. It is therefore
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possible that immune-mediated neuroprotection and
other central molecular responses to axotomy influenced
by peripheral immune status are effected by local paracrine signaling from infiltrating T cells or by direct contact between T cells and CNS resident cells in the
FMNuc. We demonstrate that CD4+ T cells often
localize with microglial nodules, which is in agreement
with other studies finding accumulation of CD3+ cells
near microglial clusters after FNA [11, 28]. Microglial
nodules in the FMNuc are associated with phagocytosis
of dead neurons and are characterized by strong MHC
class II immunoreactivity, making them potential “hotspots” for presentation of neuronal antigen and activation of infiltrating T cells [28, 29].
A previous study from our laboratory showed that both
IL-10 and CD4+ T cells are necessary for FMN survival,
but CD4+ T cells are not a required source of IL-10 in the
FNA injury model. Interestingly, RAG-2-/- mice have transiently depressed IL-10 levels in the FMNuc during the
early post-injury phase which are restored by CD4+ T cell
reconstitution [19]; however, this effect is modest, resolves
quickly, and occurs prior to significant central T cell infiltration as described by others [11, 28]. Although it is still
possible that maintenance of IL-10 expression by CNS resident cells is one mechanism by which CD4+ T cells

Fig. 10 Differentiation of a Th1, b Th2, c Th17, and d Treg helper subsets in WT (black bars) and Il10rb-/- splenocytes (white bars) stimulated with
anti-CD3, anti-CD28, PMA, and ionomycin in vitro. Subsets are shown both as percentage of cells within TCRβ + CD4 + parent population as well
as absolute cell counts calculated from percentages. Bars represent mean ± SEM. *p < 0.05
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support FMN survival, further investigation into a potential
link between IL-10-mediated and adaptive immunemediated mechanisms of neuroprotection was warranted.
The data in this study expand our knowledge of the requirements for both IL-10 and CD4+ T cells in the injured
FMNuc. Because overall levels of IL-10 in the FMNuc do
not change in response to axotomy in the WT animal [19],
induction of neuroprotective IL-10 signaling depends on
increased IL-10R expression, likely on neurons and/or astrocytes [19, 28]. CD4+ T cells may be necessary for full induction of neuroprotective IL-10 signaling by triggering
upregulation of IL-10R gene expression in the FMNuc, regardless of their own IL-10RB expression or IL-10 signaling
capability. A recent study on immune-mediated neuroprotection in the context of chemotherapy-induced peripheral
neuropathy (CIPN) bears striking similarities with our
observations after FNA. Krukowski et al. demonstrated that
CD8+ T cells and IL-10 are necessary for recovery of
normal sensation after CIPN; however, the T cell is not the
requisite source of IL-10. Rather, the presence of CD8+ T
cells is necessary for upregulation of Il10ra mRNA in dorsal root ganglion neurons after paclitaxel-induced injury
[38]. These data support a role for T cell regulation of the
IL-10 signaling cascade via induction of IL-10R expression
on neurons after peripheral nerve injury.
IL-10 has direct trophic effects on neurons, of which
various populations have been shown to express IL-10R
in vivo and in vitro [18, 19, 28, 39, 40]. Application of
exogenous IL-10 to primary cortical neurons undergoing
oxygen-glucose deprivation challenge suppresses apoptosis, promotes neurite outgrowth, and enhances synaptogenesis [39]. In cultured spinal cord neurons, IL-10R
activation prevents glutamate-induced excitotoxicity
[18]. Exogenous IL-10 treatment also improves neuron
survival in vivo after spinal cord injury through regulation of pro- and anti-apoptotic factors [41]. An increase
in neuronal IL-10R expression mediated by CD4+ T
cells may therefore have an important role in trophic
support for injured motoneurons after axotomy. The
proposal that these trophic signals must arrive centrally
via IL-10R signaling on the neuron cell body is congruent with a previous finding from our laboratory which
showed that application of exogenous IL-10 to the peripheral nerve stump fails to restore neuron survival in either IL-10-/- or RAG-2-/- mice [19]. Future studies will
investigate the effects of selective application of IL-10 to
the central compartment after axotomy.
Despite regulating IL-10R gene expression on other cells
normally, T cells that are unresponsive to IL-10 themselves via loss of the IL-10RB subunit fail to confer neuroprotection after axotomy. Although IL-10RB is considered
a promiscuous receptor subunit that is shared with some
interferon receptors and other IL-10 family cytokines, cells
lacking IL-10RB respond normally to both type I
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interferons and IFNγ, but are completely unresponsive to
IL-10 [32, 33, 42]. Loss of IL-10RB alone is sufficient to recapitulate the auto-inflammatory intestinal pathology observed in IL-10-/- animals [33]. IL-10 directly inhibits
CD28 phosphorylation in T cells and induces T cell anergy [43–47]. This loss of tolerance to self-antigen after
axotomy in Il10rb-/- CD4+ T cells could be the cause for
their failure to mediate neuroprotection.
Tolerized T cells actively suppress APCs by downregulating their expression of the antigen presentation and costimulation molecules MHC class II, CD80, and CD86 [22].
Low CD86 is associated with tolerogenic APCs and an
anti-inflammatory microglia phenotype [48–51], whereas
increased microglial MHC class II and CD86 are associated
with neurodegenerative and autoimmune conditions [52–
55]. The Il10rb-/- CD4+ T cells utilized in this study
promoted greater expression of Cd68, H2ab1, and Cd86,
suggesting that they may enhance microglial activation,
antigen presentation, and T cell co-stimulation. Loss of IL10 signaling in CD4+ T cells may dis-inhibit a deleterious
autoimmune response mediated by microglia after injury.
MHC class I immunoreactivity is highly specific to
microglial phagocytic nodule formation in the injured
FMNuc [15, 16]. FNA also activates microglial expression
of C3 mRNA and the C3 receptor [56–58]. High complement, including C3, and exaggerated synaptic pruning are
associated with neuronal death in CNS disease and injury
[59–66]. Il10rb-/- CD4+ T cells promoted expression of
both B2m and C3, implicating T cells as modulators of
microglial phagocytosis and synaptic pruning. Because
synapse elimination can be either destructive or protective
by shielding injured FMN from excitotoxic inputs [67],
the modest increase in B2m and C3 caused by WT CD4+
T cells in this study may represent a “Goldilocks zone” for
beneficial synaptic elimination after FNA. However, the
greater increases in B2m and C3 observed after transfer of
Il10rb-/- CD4+ T cells suggest that increased synaptic
elimination (or perhaps phagocytosis of stressed neurons)
may enhance neuronal death after axotomy.
Other studies have demonstrated the importance of IL10R signaling specifically in T cells. Adoptive transfer of
CD4+ T cells overexpressing a dominant-negative form of
IL-10RA into immunodeficient mice causes the development of spontaneous enterocolitis [68]. In mouse models
and in humans, T cells nonresponsive to IL-10 escape
Treg control, proliferate to a greater degree, and produce
higher amounts of inflammatory cytokines such as Th17
and IFNγ, both of which activate macrophages and promote cellular autoimmunity [68, 69]. Interestingly, IL-10R
signaling and downstream STAT3 phosphorylation are
defective in CD4+ T cells from patients with systemic
lupus erythematosus and MS, suggesting that failure of T
cell suppression by IL-10 may play an important role in
autoimmune disease, including in the CNS [70, 71].
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The harmful role of autoreactive T cells is supported by
studies finding that immunization with or without neural
antigen exacerbates motoneuron loss after spinal cord
injury and FNA, indicating an overall detrimental effect of
enhancing adaptive immune reactivity on neuron survival
[72, 73]. Those findings, as well as those described in this
study, initially appear to contradict previous results from
our laboratory that T cells must encounter MHC class II
both peripherally and centrally in order to confer neuroprotection after axotomy [6]. However, high MHC class II
expression in the absence of adequate co-stimulation may
represent a mechanism by which microglia attempt to
terminate autoreactive T cell responses [74]. Therefore,
the requirement for dual compartment MHC class II
expression for neuroprotection may actually represent the
need for deletion of certain autoreactive T cell populations
after axotomy.
The failure of Il10rb-/- CD4+ T cells to promote neuroprotection also prompted the hypothesis that loss of IL-10
signaling may result in failure of differentiation of the neuroprotective Th2 subtype. Surprisingly, the numbers of
Th1, Th2, and Th17 cells were not affected by loss of IL10RB, but a decrease in the Treg population was observed.
Although natural Tregs have been previously ruled out as
important for neuroprotection after FNA [75], these data
suggest that inducible Tregs (iTregs) may have a neuroprotective role after axotomy that is dependent on intact IL-10
signaling. However, it is important to note that interpretation of this study is limited, as T cell differentiation was
elicited by non-specific stimulation of splenocytes in vitro
rather than by FNA-associated antigen displayed on APCs.
Furthermore, it is possible that Il10rb-/- CD4+ T cells
become skewed toward a particular phenotype only after
entering an inflammatory microenvironment in the axotomized FMNuc. It is becoming increasingly recognized that
CD4+ T cell subsets do not necessarily represent terminally
differentiated cell populations, but can demonstrate considerable plasticity depending on the cytokine microenvironment [76]. Future studies will evaluate the ability of
adoptively transferred Il10rb-/- CD4+ T cells to differentiate
in vivo into T cell subsets (including iTregs) after FNA.

Conclusions
Neuroprotective CD4+ T cells infiltrate the FMNuc after
axotomy and are required for full induction of central IL10R expression. CD4+ T cells lacking IL-10RB fail to confer
neuroprotection after axotomy and promote a microglial
gene signature associated with enhanced antigen presentation, T cell co-stimulation, and synaptic elimination. An
autoimmune response to axotomy may also be exacerbated
by decreased iTreg numbers in Il10rb-/- mice. These results
suggest that although the degree of neuronal death in immunodeficient mice and mice reconstituted with Il10rb-/CD4+ T cells is comparable, the causes of FMN death are
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likely quite distinct. In immunodeficient mice, the neuroprotective Th2 subset is absent, and there is a blunted glial
response to axotomy [4, 5]. In contrast, mice given Il10rb-/CD4+ T cells may exhibit dis-inhibition of a harmful autoimmune response that promotes microglial hyperresponsiveness to injury. In the spectrum of immune responses that can occur after axotomy, neither extreme is favorable, and optimum FMN survival likely depends on
balanced activation of immune effectors.
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